StemCell Institute Inc. (TYO:7096)

Market Cap	6.91B -44.3%
Revenue (ttm)	2.81B +4.9%
Net Income	155.00M -59.7%
EPS	15.35 -59.2%
Shares Out	10.25M
PE Ratio	43.91
Forward PE	61.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,300
Open	675.00
Previous Close	674.00
Day's Range	667.00 - 678.00
52-Week Range	627.00 - 1,245.00
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About StemCell Institute

StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of new cell-based treatments, and pharmaceuticals and medical devices. It also engages in cell contract management and transportation business; extraction, purification, processing, storage, testing and sales of biological tissue-derived components; and medical facility operation and management business. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 117
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 7096

Financial Performance

In fiscal year 2026, StemCell Institute's revenue was 2.81 billion, an increase of 4.93% compared to the previous year's 2.68 billion. Earnings were 155.00 million, a decrease of -59.74%.